Nigeria: U.S. Health Deal Under Scrutiny After Ghana Rejects Similar Pact

• Nigeria's $5 billion health agreement with the U.S. is under scrutiny following Ghana's rejection of a similar deal.
• The Memorandum of Understanding (MoU) requires Nigeria to share health outcomes data and pathogen specimens with the U.S. government.
• A controversial clause allows the U.S. to retain use of shared data even if Nigeria terminates the agreement.
• Ghanaian President John Dramani Mahama revealed his country rejected a comparable $100 million compact due to concerns over data sharing, medical records, and inspection rights.
• The U.S. Embassy stated the MoU aims to advance the "America First Global Health Strategy" and involves $2.1 billion in U.S. health aid.

The requirement for Nigeria to share sensitive health outcomes and pathogen specimen data, alongside the controversial provision allowing the U.S. to retain data usage rights post-termination, has sparked a vital conversation about the long-term implications for Nigeria's public health infrastructure and its autonomy.

Nigeria has entered into a significant health agreement with the United States, valued at approximately $5 billion, which has recently drawn considerable attention. This Memorandum of Understanding (MoU), signed on December 19, 2025, outlines a five-year collaboration designed to advance the "America First Global Health Strategy." This strategy aims to enhance American safety, strength, and prosperity through international health diplomacy and foreign assistance via bilateral arrangements.

The financial framework of the deal involves a substantial commitment from both nations. The United States is set to provide nearly $2.1 billion in health aid, complemented by a counter-funding contribution of approximately $3 billion from the Nigerian government. The primary objective of this joint investment is to broaden access to affordable, preventive, and curative healthcare services. Specific health challenges targeted include HIV/AIDS, tuberculosis (TB), malaria, polio, and critical maternal and child health initiatives.

Initially, the federal government did not release extensive details regarding the agreement at the time of its signing. However, the pact has since become a subject of widespread discussion, particularly following recent comments made by Ghanaian President John Dramani Mahama, which brought similar international health compacts into the spotlight.

The scrutiny surrounding Nigeria's health agreement intensified after Ghanaian President John Dramani Mahama disclosed that his country had previously rejected a comparable health compact. Speaking on September 25 at the Council on Foreign Relations in New York, on the sidelines of the 81st United Nations General Assembly, President Mahama revealed that Ghana declined a proposed agreement exceeding $100 million due to significant concerns identified by its health ministry.

President Mahama detailed several "humiliating" provisions within the compact, which was intended to replace existing funding from the U.S. State Department, which absorbed the functions of the United States Agency for International Development (USAID) in July 2025. Among the critical issues flagged were requirements for Ghana to share its pathogen profile, detailing endemic diseases and ensuring compliance with American standards. Furthermore, the agreement demanded access to Ghanaian medical records, a stipulation Mahama found particularly "strange."

Additional contentious clauses included a mandate for Ghana to allocate a specific financial contribution to healthcare as part of the program, and a provision that would strip the Ghanaian Food and Drugs Administration (FDA) of any authority to inspect medications or medical products imported under the compact. Following a thorough review by the health ministry and subsequent discussion via a Cabinet Information Paper, Ghana's cabinet swiftly rejected the proposal, with the health minister instructed to inform the U.S. ambassador of their decision.

The concerns raised by Ghana's experience resonate with specific provisions identified within the Nigeria-U.S. Memorandum of Understanding. Investigations by Daily Trust indicate that the Nigerian agreement mandates the sharing of health outcomes data and biological specimens related to novel and emerging infectious diseases with the United States government. This data-sharing aspect is a central point of contention.

Further exacerbating these concerns, medical experts have criticized a particular section of the specimen sharing agreement. This clause stipulates that the United States would retain the right to utilize the shared data even if Nigeria were to terminate the overall agreement. This provision raises questions about data sovereignty and long-term control over sensitive health information.

In response to the growing discourse, the U.S. Embassy and Consulate in Nigeria issued a statement clarifying the MoU's objectives. The statement affirmed that the agreement is designed to "advance the America First Global Health Strategy," emphasizing its role in fostering resilient, self-reliant, and durable health systems while promoting accountability and shared responsibility between the two nations. The Embassy reiterated that the U.S. intends to commit nearly $2.1 billion over the five-year period to support key areas such as surveillance and outbreak response, laboratory systems, health commodities, frontline healthcare workers, and data systems.

The unfolding situation surrounding the Nigeria-U.S. health deal, particularly in light of Ghana's prior rejection of a similar compact, underscores significant questions regarding national health sovereignty and data control. The "America First Global Health Strategy," while framed as a means to enhance global health, is explicitly designed to benefit American interests through bilateral agreements. This framing, coupled with the specific clauses identified in the Nigerian MoU, highlights a potential imbalance in control over critical health data and resources.

The requirement for Nigeria to share sensitive health outcomes and pathogen specimen data, alongside the controversial provision allowing the U.S. to retain data usage rights post-termination, has sparked a vital conversation about the long-term implications for Nigeria's public health infrastructure and its autonomy. The lack of detailed public disclosure at the initial signing further fueled public and expert scrutiny, emphasizing the need for transparency in international health agreements that involve such extensive data exchange and financial commitments. The experiences of both Ghana and Nigeria bring to the forefront the complex interplay between international aid, national sovereignty, and the protection of sensitive health information in global health partnerships.

Source: Original reporting via Daily Trust